Chronic Obstructive Lung Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic obstructive lung disease. 73 active patents protecting 4 drugs from 4+ originators. First major cliff: 2027. Daily refresh.

4
Approved drugs
73
Active US patents
55/100
Avg vulnerability
$3.1B
Annual revenue covered

Originators in Chronic Obstructive Lung Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Haleon Us Holdings 41 patents Yonsei University 18 patents Mylan Ireland Ltd 10 patents Covis 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic obstructive lung disease. Each bar = one year. Y-axis scaled to peak year (26 patents).

1
26
8
27
8
28
11
29
26
30
6
31
1
32
1
33
1
35
2
36
5
38
3
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Arnuity Ellipta
FLUTICASONE FUROATE
 Haleon Us Holdings 41 61 $3.1B 2027-06-14
Glycopyrrolate Yonsei University 18 53 — 2026-08-16
Yupelri
REVEFENACIN
 Mylan Ireland Ltd 10 47 — 2028-10-31
Tudorza Pressair
ACLIDINIUM BROMIDE
 Covis 4 58 — 2029-03-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8511304 Arnuity Ellipta method of use 83 2027-06-14
11116721 Arnuity Ellipta method of use 83 2029-02-26
11858898 Yupelri method of use 81 2030-07-14
8511304 Arnuity Ellipta method of use 80 2027-06-14
8511304 Arnuity Ellipta method of use 75 2027-06-14
8511304 Arnuity Ellipta other 75 2027-12-14
8511304 Arnuity Ellipta other 75 2027-12-14
8511304 Arnuity Ellipta other 75 2027-12-14
11116721 Arnuity Ellipta method of use 75 2029-02-26
11116721 Arnuity Ellipta method of use 75 2029-02-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8541451 Yupelri composition of matter 10 2031-08-25
9765028 Yupelri composition of matter 10 2030-07-14
10550081 Yupelri composition of matter 10 2030-07-14
7288657 Yupelri composition of matter 17 2028-10-31
7488827 Arnuity Ellipta composition of matter 17 2027-12-18
7488827 Arnuity Ellipta composition of matter 17 2027-12-18
10688518 Glycopyrrolate formulation 42 2036-11-12
10376661 Glycopyrrolate formulation 42 2035-09-14
9604018 Glycopyrrolate formulation 42 2033-05-16
9168556 Glycopyrrolate formulation 42 2032-09-01

Related